Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis.
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
01
08
2018
revised:
26
08
2018
accepted:
29
08
2018
pubmed:
22
9
2018
medline:
22
9
2018
entrez:
22
9
2018
Statut:
ppublish
Résumé
Presurgical carbohydrate antigen 19-9 (CA19-9) level predicts overall survival (OS) in resected pancreatic adenocarcinoma (PaC). The aim of this pooled analysis was to evaluate if presurgical CA19-9 level can also predict local control (LC) and distant metastasis-free survival (DMFS). Seven hundred patients with PaC from eight institutions who underwent surgical resection ± adjuvant treatment between 2000 and 2014 were analyzed. Patients were divided based on four presurgical CA19-9 level cutoffs (5, 37, 100, 353 U/ml). Weibull regression model to identify independent predictors of OS on 404 patients with complete information was fitted. Median follow-up was 17 months (range: 2-225 months). Univariate analysis showed a better prognosis in pT1-2, pN0, diameter <30 mm, or grade 1 tumors and in patients undergoing R0 resection, distal pancreatectomy, or adjuvant chemotherapy and with lower CA19-9 levels. Five-year OS, LC, and DMFS were as follows: CA19-9 <5.0: 5.7%, 47.2%, 17.0%; CA19-9 5.1-37.0: 37.9%, 63.3%, 46.0%; CA19-9 37.1-100.0: 27.1%, 59.4%, 39.0%; CA19-9 100.1-353.0: 17.4%, 43.4%, 26.7%; CA19-9 >353.1: 10.9%, 50.2%, and 23.4%, respectively. At multivariate analysis, CA19-9 >100 and <353 level (P=.002), CA19-9 ≥353.1 (P<.001) level, G3 tumor (P=.002), and tumor diameter >30 mm (P<.001) correlated with worse OS. Patients treated with postoperative chemoradiation doses >50.0 Gy showed improved OS (P<.001). Presurgical CA19-9 predicts both OS and pattern of failure. Therefore, CA19-9 should be included in predictive models in order to customize treatments based on prognostic factors. Moreover, future studies should stratify patients according to presurgical CA19-9 level.
Sections du résumé
BACKGROUND
BACKGROUND
Presurgical carbohydrate antigen 19-9 (CA19-9) level predicts overall survival (OS) in resected pancreatic adenocarcinoma (PaC). The aim of this pooled analysis was to evaluate if presurgical CA19-9 level can also predict local control (LC) and distant metastasis-free survival (DMFS).
METHODS
METHODS
Seven hundred patients with PaC from eight institutions who underwent surgical resection ± adjuvant treatment between 2000 and 2014 were analyzed. Patients were divided based on four presurgical CA19-9 level cutoffs (5, 37, 100, 353 U/ml). Weibull regression model to identify independent predictors of OS on 404 patients with complete information was fitted.
RESULTS
RESULTS
Median follow-up was 17 months (range: 2-225 months). Univariate analysis showed a better prognosis in pT1-2, pN0, diameter <30 mm, or grade 1 tumors and in patients undergoing R0 resection, distal pancreatectomy, or adjuvant chemotherapy and with lower CA19-9 levels. Five-year OS, LC, and DMFS were as follows: CA19-9 <5.0: 5.7%, 47.2%, 17.0%; CA19-9 5.1-37.0: 37.9%, 63.3%, 46.0%; CA19-9 37.1-100.0: 27.1%, 59.4%, 39.0%; CA19-9 100.1-353.0: 17.4%, 43.4%, 26.7%; CA19-9 >353.1: 10.9%, 50.2%, and 23.4%, respectively. At multivariate analysis, CA19-9 >100 and <353 level (P=.002), CA19-9 ≥353.1 (P<.001) level, G3 tumor (P=.002), and tumor diameter >30 mm (P<.001) correlated with worse OS. Patients treated with postoperative chemoradiation doses >50.0 Gy showed improved OS (P<.001).
CONCLUSION
CONCLUSIONS
Presurgical CA19-9 predicts both OS and pattern of failure. Therefore, CA19-9 should be included in predictive models in order to customize treatments based on prognostic factors. Moreover, future studies should stratify patients according to presurgical CA19-9 level.
Identifiants
pubmed: 30237099
pii: S1936-5233(18)30360-7
doi: 10.1016/j.tranon.2018.08.017
pmc: PMC6143718
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-7Informations de copyright
Copyright © 2018. Published by Elsevier Inc.
Références
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):911-7
pubmed: 25220717
Int J Cancer. 2015 May 1;136(9):2216-27
pubmed: 25273947
Arch Biochem Biophys. 2004 Jun 15;426(2):122-31
pubmed: 15158662
Ann Surg Oncol. 2004 Jul;11(7):644-9
pubmed: 15197014
J Gastrointest Oncol. 2012 Jun;3(2):105-19
pubmed: 22811878
World J Gastroenterol. 2014 Aug 28;20(32):11210-5
pubmed: 25170205
N Engl J Med. 2010 Apr 29;362(17):1605-17
pubmed: 20427809
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
J Surg Oncol. 2015 Mar;111(3):293-8
pubmed: 25330934
Ann Oncol. 2010 Mar;21(3):441-7
pubmed: 19690057
J Gastrointest Surg. 2012 May;16(5):977-85
pubmed: 22411488
Am J Clin Oncol. 2011 Dec;34(6):567-72
pubmed: 21150564
Ann Surg Oncol. 2010 Sep;17(9):2321-9
pubmed: 20336387
HPB (Oxford). 2014 May;16(5):430-8
pubmed: 23991810
Ann Surg Oncol. 2013 Jul;20(7):2188-96
pubmed: 23247983
Clin Chem. 1999 Jan;45(1):54-61
pubmed: 9895338
Eur J Surg Oncol. 2002 Aug;28(5):523-30
pubmed: 12217306
Ann Oncol. 2014 Aug;25(8):1650-6
pubmed: 24759568
World J Surg Oncol. 2014 Jun 02;12:171
pubmed: 24890327
J Surg Oncol. 2007 Feb 1;95(2):142-7
pubmed: 17262731
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e743-8
pubmed: 21129857
Ann Surg Oncol. 2009 Dec;16(12):3316-22
pubmed: 19707831
Ann Surg Oncol. 2009 May;16(5):1231-40
pubmed: 19263172
World J Gastroenterol. 2008 Jun 21;14(23):3750-3
pubmed: 18595144
Somatic Cell Genet. 1979 Nov;5(6):957-71
pubmed: 94699
J Clin Oncol. 2006 Jun 20;24(18):2897-902
pubmed: 16782929